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ABSTRACT
Background The immune contexture predicts
prognosis in human colorectal cancer (CRC). Whereas
tumour-inﬁltrating CD8+ T cells and myeloid CD16+
myeloperoxidase (MPO)+ cells are associated with
favourable clinical outcome, interleukin (IL)-17-producing
cells have been reported to correlate with severe
prognosis. However, their phenotypes and functions
continue to be debated.
Objective To investigate clinical relevance, phenotypes
and functional features of CRC-inﬁltrating, IL-17-
producing cells.
Methods IL-17 staining was performed by
immunohistochemistry on a tissue microarray including
1148 CRCs. Phenotypes of IL-17-producing cells were
evaluated by ﬂow cytometry on cell suspensions
obtained by enzymatic digestion of clinical specimens.
Functions of CRC-isolated, IL-17-producing cells were
assessed by in vitro and in vivo experiments.
Results IL-17+ inﬁltrates were not themselves
predictive of an unfavourable clinical outcome, but
correlated with inﬁltration by CD8+ T cells and CD16+
MPO+ neutrophils. Ex vivo analysis showed that tumour-
inﬁltrating IL-17+ cells mostly consist of CD4+ T helper
17 (Th17) cells with multifaceted properties. Indeed,
owing to IL-17 secretion, CRC-derived Th17 triggered
the release of protumorigenic factors by tumour and
tumour-associated stroma. However, on the other hand,
they favoured recruitment of beneﬁcial neutrophils
through IL-8 secretion and, most importantly, they drove
highly cytotoxic CCR5+CCR6+CD8+ T cells into tumour
tissue, through CCL5 and CCL20 release. Consistent
with these ﬁndings, the presence of intraepithelial, but
not of stromal Th17 cells, positively correlated with
improved survival.
Conclusions Our study shows the dual role played by
tumour-inﬁltrating Th17 in CRC, thus advising caution
when developing new IL-17/Th17 targeted treatments.
INTRODUCTION
The tumour immune contexture—that is, type,
location, density and functional orientation of
tumour-inﬁltrating immune cells,1 predicts clinical
outcome in human colorectal cancer (CRC). In par-
ticular, CD45RO+ memory T lymphocytes, cyto-
toxic CD8+ T cells (CTLs) and interferon
(IFN)-γ-producing T helper 1 cells (Th1) have been
found to be associated with prolonged survival,
irrespective of tumour stage (5–7). Unexpectedly,
Foxp3+ regulatory T cells (Tregs),2 3 CD16+ and
myeloperoxidase (MPO)+ myeloid cells,4–6 also
Signiﬁcance of this study
What is already known on this subject?
▸ Inﬁltration of colorectal cancers (CRCs) by
deﬁned populations of immune cells predicts
clinical outcome irrespective of tumour stage.
▸ CRC-inﬁltrating CD8+ T cells and CD16+
myeloperoxidase (MPO)+ neutrophils have been
found to be associated with prolonged survival,
whereas inﬁltration by interleukin
(IL)-17-producing cells, as evaluated in a
limited number of cases, has been suggested to
correlate with more severe prognosis.
▸ IL-17 is a proinﬂammatory cytokine mediating
protumorigenic and proangiogenic effects.
▸ Monoclonal antibodies targeting IL-17/
IL-17-receptor or impairing expansion of
IL-17-producing cells may represent a new
therapeutic option in CRC.
What are the new ﬁndings?
▸ Analysis of a large cohort of CRCs shows that
tumour-inﬁltrating IL-17-producing cells are not
themselves predictive of poor clinical outcome.
▸ Intraepithelial localisation of CRC-inﬁltrating
IL-17+ cells is associated with improved survival.
▸ CRC inﬁltration by IL-17+ cells correlates with
the presence of beneﬁcial CD8+ T cells and
CD16+ MPO+ neutrophils.
▸ CRC-inﬁltrating IL-17+ cells, mostly consisting
of polyfunctional T helper 17 cells (Th17), can
recruit highly cytotoxic CD8+ T cells into
tumour nests through CCL5 and CCL20 release.
How might it impact on clinical practice in
the foreseeable future?
▸ By disclosing the dual role played by CRC-Th17,
our ﬁndings question therapeutic approaches
aimed at inhibiting Th17 development or
expansion, possibly resulting in impaired
tumour inﬁltration by beneﬁcial effector cells.
The positive contribution of Th17 to
anti-tumour immune responses should not be
disregarded when developing new IL-17/Th17
targeted treatments in CRC.
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correlate with favourable clinical outcome. In contrast, tumour
inﬁltration by interleukin (IL)-17A-producing cells, evaluated so
far in a limited number of cases (50–200), appears to be asso-
ciated with unfavourable prognosis.7 8
IL-17A (hereafter referred to as IL-17) is an inﬂammatory
cytokine, secreted by different cell types, including CD4+ T
helper cells (Th17),9 10 CTLs, γδT cells, Tregs,11–13 natural killer
(NK) cells, NKT cells, lymphoid tissue inducer (LTi)-like cells
and neutrophils.14 15 IL-17 plays a prominent role in protective
immune responses against bacterial and fungal infections and in
the pathogenesis of inﬂammatory disorders.9 10 16
Experimental models indicate that IL-17 promotes intestinal
tumorigenesis,17–22 either by favouring proliferation of aberrant
epithelial cells21 or by inducing IL-6 release by tumour-associated
stroma.18 Furthermore, IL-17 promotes angiogenesis through
vascular endothelial growth factor (VEGF) production,18 20 thus
mediating tumour resistance to antiangiogenic treatments.18
Monoclonal antibodies targeting IL-17/IL-17-receptor, or
cytokines, such as IL-23, supporting Th17 development, have
been recently developed and their clinical application in several
inﬂammatory and autoimmune diseases is being evaluated.23–25
These reagents may provide a new therapeutic option in
CRC.26 However, before testing IL-17/Th17-targeted treat-
ments, a more comprehensive analysis of CRC-inﬁltrating,
IL-17-producing cells is required.27
We evaluated the prognostic signiﬁcance of IL-17 in a tissue
micro-array (TMA) including 1148 CRC cases and we investi-
gated phenotypes and functions of CRC-derived IL-17+ cells.
Here we show that CRC-inﬁltrating IL-17-producing cells,
mainly consisting of polyfunctional Th17, do not themselves
predict clinical outcome, but rather play a dual role. On the one
hand, owing to IL-17 secretion, they favour release of protu-
morigenic factors by tumour and tumour-associated stroma.
However, on the other hand, they promote recruitment of bene-
ﬁcial neutrophils and CTLs by secreting speciﬁc chemokine and
cytokine patterns. Interestingly, the presence of intraepithelial
Th17 was signiﬁcantly associated with patient survival, consist-
ent with the ability of Th17 to drive beneﬁcial immune cells into
the tumour. The potential contribution of tumour-inﬁltrating
Th17 to anti-tumour immune responses should not be disre-
garded when considering new IL-17/Th17 targeted treatments.
MATERIALS AND METHODS
Immunohistochemistry
A previously described TMA, including 1420 non-consecutive
primary CRCs and 71 normal colonic mucosa samples,2 4–6 28
was stained with a goat polyclonal anti-human IL-17 antibody
(R&D Systems; staining I). IL-17 expression was evaluable in
1151 CRCs and 39 healthy mucosa samples. A randomised sub-
group, including 746 CRCs and 27 healthy mucosa cases, was
stained with a rabbit polyclonal anti-human IL-17 antibody
(H-132, Santa Cruz Biotechnology; staining II). Secondary stain-
ings and negative controls were performed as described.29
Protein markers were scored by three observers (AL, FA and
FT). Cases were classiﬁed in four groups, according to numbers
of positive cells/punch (0, 1–10, 11–50, >50). Staining proto-
cols for CD8, CD16 and MPO have been previously
reported.4 6 28 Clinical information (see online supplementary
table S1) was retrieved from patient records. The use of this
information was approved by local ethical authorities.
Clinical specimen collection and processing
Clinical specimens were collected from consenting patients
undergoing surgical treatment at Basel University Hospital,
St Claraspital Basel, Kantonsspital Olten, Kantonsspital St
Gallen and Ospedale Civico Lugano. Tumour and correspond-
ing tumour-free mucosa fragments were snap-frozen for RNA
extraction or enzymatically digested (2 mg/mL collagenase IV,
Worthington Biochemical Corporation and 0.2 mg/mL DNAse I,
Sigma-Aldrich, for 1 h at 37°C) to obtain single cell
suspensions.
Flow cytometry and cell sorting
Cell suspensions from CRCs and tumour-free mucosa, and per-
ipheral blood mononuclear cells (PBMC) of healthy donors
(HDs) or patients with CRC, were incubated with 50 ng/mL
phorbol 12-myristate 13-acetate, 1 μg/mL ionomycin and 5 μg/
mL brefeldin A (Sigma-Aldrich) for 5 h. Cells were ﬁxed and
surface stained with ﬂuorochrome-conjugated antibodies speciﬁc
for human CD3, CD4, CD8, CD45RO, CD56, CD127, CCR6,
HLA-DR, γδTCR (all from BD Biosciences), V α 24 J α 18 TCR
(eBioscience) and CD66b (BioLegend). Intracellular staining was
then performed with antibodies speciﬁc for human IL-17
(eBioscience), IFN-γ, tumour necrosis factor (TNF)-α, IL-22,
IL-21, IL-8 (all from BD Biosciences) or granulocyte-
macrophage colony stimulating factor (GM-CSF) and Foxp3
(BioLegend).
Chemokine receptor expression on CD8+ T cells was evalu-
ated in CRC samples and autologous PBMC by surface stain-
ing with anti-human CCR5, CCR6 and CXCR3 antibodies
(BD Biosciences). Stained cells were analysed by FACSCalibur
ﬂow cytometer (BD Biosciences) and FlowJo software (Tree
Star).
Tumour, endothelial and mesenchymal cells were sorted from
CRC cell suspensions using a BD Inﬂux (BD Biosciences), upon
staining with EpCAM-, CD31- and CD90-speciﬁc antibodies
(BD Biosciences), respectively.
T cell expansion and cloning
CRC-isolated T lymphocytes were stimulated with 1 μg/mL of
phytohaemagglutinin (Sigma-Aldrich) and expanded in medium
supplemented with 100 IU/mL IL-2 (Roche Applied Science)
and 5% of pooled human AB serum (provided by
Blutspendenzntrum Beider Basel, Basel University Hospital) for
20 days. Th17 cells, identiﬁed based on CD4+ CXCR3-CCR4
+CCR6+ phenotype,30 were sorted by ﬂow cytometry and
further expanded as bulk populations. Th17 clones (hereafter
referred to as CRC-Th17) were subsequently generated from
bulk populations by limiting dilution. Supernatants from Th17
bulk populations and clones were obtained by T cell activation
with plate bound anti-CD3 (10 μg/mL, clone UCHT1,
eBioscience) and soluble anti-CD28 antibodies (1 μg/mL, clone
CD28.2, BD Biosciences). After overnight culture, supernatants
were collected and used for determination of cytokine contents
by ELISA and for migration assays.
Real-time reverse-transcription PCR
Total RNA was extracted from tissues or sorted cells using the
RNeasy Mini Kit protocol (Qiagen), treated with DNAse I
(Invitrogen) and reverse transcribed using the Moloney murine
leukemia virus reverse transcriptase (M-MLV RT, Invitrogen).
Quantitative real-time PCR was performed in the ABI prism
7700 sequence detection system, using TaqMan Universal Master
Mix and No AmpErase UNG (both from Applied Biosystems).
Commercially available primers and probes speciﬁc for human
IL-17A (Hs99999082_m1), CCL5 (Hs00982282_m1), CXCL9
(Hs00171065_m1) and CXCL10 (Hs99999049_m1, all from
Applied Biosystems) were used.
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Cell lines
Human CRC cell lines LS180, COLO205 and HT29, purchased
from the European Collection of Cell Cultures, were maintained
in RPMI 1640 (GIBCO) or, for HT29, McCoy’s 5A medium
(Sigma-Aldrich), supplemented with 10% fetal bovine serum,
GlutaMAX-I and kanamycin (GIBCO). HMEC cells (provided
by Professor T Resink, University of Basel) were cultured in
EBM-2 medium (Lonza). Tumour-associated stromal cells
(TASC) were expanded from CRC samples in α-MEM (GIBCO)
supplemented with 10% fetal bovine serum and 5 ng/mL FGF-2
(R&D Systems).
In vitro migration assay
Migration of neutrophils, isolated from PBMC of HDs by mag-
netic beads (EasyStep enrichment kit, StemCell Technologies),
was assessed in transwell plates (5 mm pore size, Corning
Costar), towards Th17 supernatants or recombinant cytokines
(IL-17, R&D Systems, 50 ng/mL; IL-8, R&D Systems, 100 ng/
mL; GM-CSF, R&D Systems, 100 ng/mL), for 90 min at 37°C.
In speciﬁc experiments, anti-IL-8 or anti-GM-CSF antibodies
(10 μg/mL, R&D Systems) were added to Th17 supernatants.
Migration of CD8+ T cells, sorted from PBMC of HDs by
magnetic microbeads (Miltenyi Biotec) and pre-activated over-
night with anti-CD3/CD28 antibodies, was evaluated in trans-
well plates (5 mm pore size) towards Th17 supernatants,
supernatants of HMEC cells, untreated, or exposed overnight to
Th17 supernatants or recombinant proteins (IL-17, 50 ng/mL;
TNF-α, 1 ng/mL, R&D Systems; IFN-γ, 1 ng/mL, Biolegend; or
their combination), or towards CCL5 (60 and 200 ng/mL, R&D
Systems) and/or CCL20 (300 and 1000 ng/mL, R&D Systems).
Depletion of CCL5 and/or CCL20 from Th17-derived superna-
tants was obtained by speciﬁc capture antibodies (R&D
Systems). Cell migration was quantiﬁed by ﬂow cytometry.
ELISA
Cytokine/chemokine contents in supernatants were assessed by
ELISA using CCL5, CCL20, CXCL10 and VEGF DuoSet
ELISA (all from R&D Systems) and IL-6-speciﬁc reagents (BD
Biosciences).
T cell migration into engineered tumours
Tridimensional tumour tissues were engineered in a previously
described bioreactor system.31 HT29 cells (1×106) were
injected and perfused through a collagen scaffold (Ultrafoam
Avitene Collagen Hemostat, Davol Inc). At day 7, 5×106
CRC-Th17 cells were injected and, after overnight incubation,
were activated by CytoStim (Miltenyi Biotec) for 3 h. After
extensive washing, perfusion was stopped and CD8+CD45RO
+, sorted from PBMC of HDs, were then injected and allowed
to spontaneously migrate overnight. Tissues were enzymatically
digested and analysed by ﬂow cytometry. Additionally,
parafﬁn-embedded or cryosections were collected for H&E
staining and immunoﬂuorescence analysis.
Histological and immunoﬂuorescence analysis
Parafﬁn sections (5 μm) were stained with H&E and analysed by
light microscopy. Cryosections (10 μm) were incubated with
rabbit polyclonal anti-human CD8 (Abcam) and mouse mono-
clonal anti-human CD4 (DakoCytomation) antibodies, or with
rabbit polyclonal anti-human IL-17 (H-132, Santa Cruz
Biotechnology) and mouse monoclonal EpCAM (Cell
Signalling), followed by secondary species-speciﬁc Alexa Fluor
488- or Alexa Fluor 547-conjugated antibodies (Invitrogen).
Nuclei were counterstained with 4,6-diamidino-2-phenylindole.
Sections were examined under an Olympus BX61 ﬂuorescence
microscope (Olympus) and images captured with 10× and 20×
magniﬁcations using a F-VIEW II camera (Olympus) and
AnalySIS software (Soft Imaging System GmbH).
In vivo migration assay
LS180 cells were inoculated subcutaneously in 8-week-old NSG
mice (Charles River, Germany). CRC-Th17 and CD8+ T cells,
isolated from PBMC of HDs, were activated overnight with
anti-CD3/CD28 antibodies. Carboxyﬂuorescein succinimidyl
ester-labelled CD8+ T cells were adoptively transferred by intra-
venous injection in tumour-bearing mice (maximum tumour
volume 1 cm3) alone or together with Th17 (5×106 cells/
subset/mouse). After 48 h, tumours were harvested and frequen-
cies of CD8+CSFE+ T cells in tumour cell suspensions were
evaluated by ﬂow cytometry.
Statistical analysis
CRC cases were classiﬁed into four categories according to
numbers of IL-17+ cells/punch (0; 1–10; 11–50; >50). Speciﬁc
cut-off values for CD8, CD16 and MPO (10, 50 and 60,
respectively) were obtained by receiver operating curve (ROC)
analysis.4 6 28
A χ2 test was used to determine the signiﬁcance of differences
between dichotomous variables. Survival analysis was depicted
by Kaplan–Meier method and compared with log-rank test.
Statistical analyses were performed using R (V.2.15.2, http://
www.r-project.org).
Differences in frequencies of IL-17+ cells within PBMC of
HDs or patients with CRC and between tumour and control
tissues were evaluated by t test. Differences in migration rates
and cytokine release were tested by one way analysis of variance
using GraphPad Prism5 (GraphPad Software).
RESULTS
CRC-inﬁltrating IL-17+ cells do not predict clinical outcome
IL-17+ cells were evaluated by immunohistochemistry upon
staining of a characterised TMA (38–39 and see online supple-
mentary table S1) with two different polyclonal anti-IL-17 anti-
bodies (staining I, ﬁgure 1A and staining II, see online
supplementary ﬁgure S1A). Results obtained from the two stain-
ings showed good and signiﬁcant correlation (r=0.436
p<0.00001, weighted Cohen κ=0.284). IL-17+ cells were
detectable within epithelial and stromal compartments.
Numbers of intraepithelial IL-17+ cells were signiﬁcantly
higher in tumour samples than in normal colonic mucosa
(ﬁgure 1Β). Accordingly, higher IL-17 mRNA levels in CRC
than in corresponding control tissues were detected (see online
supplementary ﬁgure S1B).
No association between IL-17+ inﬁltrates and tumour loca-
tion, mismatch repair status or tumour border conﬁguration was
seen (table 1). In a limited group of cases for which additional
clinical information was available, no correlation between
numbers of IL-17+ cells and local recurrences (n=446), or
distant metastasis (n=452) was seen (table 1). In contrast, IL-17
+ cells strongly correlated with peritumoral lymphocytic inﬁl-
tration (p<0.001). A slight increase in IL-17+ cell numbers was
seen in tumours characterised by early T and N stage, low grade
and absence of vascular invasion. Unexpectedly, no signiﬁcant
impact of IL-17+ cells on overall survival (ﬁgure 1C left panel,
n=1151 and see online supplementary ﬁgure S1C, n=649) or
relapse-free survival (ﬁgure 1C right panel, n=443) was seen.
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Tumour inﬁltration by IL-17+ cells is associated with the
presence of CTLs and neutrophils
Interestingly, IL-17 was found to correlate signiﬁcantly with
CD16, MPO and CD8 markers (ﬁgure 1D), predictive of
improved survival in the same TMA.4 6 32 CD16 and MPO are
expressed in a subset of HLA-DR- CD15+ CD66b+ myeloid
cells, mostly including activated neutrophils.4 6 Indeed, numbers
of IL-17+ cells also correlated with those of inﬁltrating poly-
morphonuclear cells (see online supplementary ﬁgure S1D).
We wondered whether the positive impact of these popula-
tions might mask the negative prognostic signiﬁcance of IL-17+
cells. However, also in cases stratiﬁed for CD16, MPO or CD8
expression, no effect of IL-17 on survival was found (see online
supplementary ﬁgure S2).
Figure 1 Tumour inﬁltration by interleukin-17 (IL-17)-producing cells does not predict survival in colorectal cancer (CRC). IL-17 expression was
evaluated by immunohistochemistry on a tissue microarray (TMA) including 1151 cases of primary CRC. (A) Representative pictures of IL-17 staining
I (see ‘Materials and methods’). Numbers of IL-17+ cells per punch are indicated. (B) Distribution of IL-17+ cells within the epithelial or stromal
fraction of healthy colonic tissues (Ctr) or tumour samples (T). Statistical signiﬁcance was assessed by χ2 test. (C) Kaplan–Meier curves illustrating
overall survival (OS, left panel) and relapse-free survival (RFS, right panel) probability according to IL-17+ cell density. Numbers of deaths/total cases
within each category are indicated. Statistical signiﬁcance was assessed by log-rank test. (D) Numbers of IL-17+ cells within CRC cases characterised
by low or high inﬁltration of CD16+, MPO+ and CD8+ cells, according to cut-off scores identiﬁed by receiver operating characteristic curve analysis,
as described in ‘Materials and methods’. Statistical signiﬁcance was assessed by χ2 test. MPO, myeloperoxidase.
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CRC-inﬁltrating IL-17+ cells consist of Th17 cells
We next assessed phenotypes of CRC-inﬁltrating IL-17+ cells,
in freshly isolated clinical specimens, by ﬂow cytometry
(ﬁgure 2). IL-17 production was exclusively observed within
CD3+ T cells, whose large majority expressed CD4, CD45RO
and CCR6 (ﬁgure 2A, B). Interestingly, 27±24% of inﬁltrating
IL-17+ cells also expressed Foxp3 (ﬁgure 2A, B). Sporadically,
IL-17+ CD8+ T cells were detected (ﬁgure 2A, B).
Large proportions of γδT cells and CD66b+ neutrophils (up
to 24±5% and 13±9%, respectively) were detectable, but only
a minor fraction (<1%) of those cell types showed evidence of
IL-17 production. CD56+NK, Vα24/Jα18TCR+NKT and CD3
−CD127+ LTi-like cells were detected in limited numbers
and did not include signiﬁcant fractions of IL-17+ cells (ﬁgure
2A, B). Evaluation of absolute cell numbers conﬁrmed that
the large majority of IL-17+ cells were CD3+ cells (see online
supplementary ﬁgure S3). Thus, CRC-inﬁltrating, IL-17-
producing cells mainly consist of memory Th17.
Th17 frequencies were signiﬁcantly higher in tumours than in
corresponding healthy tissues or autologous PBMC, whereas no
signiﬁcant difference was observed between PBMC of patients
with CRC and HD (ﬁgure 2C).
Importantly, a signiﬁcant fraction of CRC-inﬁltrating Th17
also produced TNF-α, IL-21, IL-22, GM-CSF, IFN-γ, and IL-8
(ﬁgure 2D, E). Th17 clones expanded from CRC-inﬁltrating
CD4+ T cells (CRC-Th17) also released TNF-α, IL-21, IL-22,
GM-CSF, IFN-γ and IL-8, in addition to IL-17 (see online sup-
plementary ﬁgure S4), thus indicating that CRC-inﬁltrating
Th17 are polyfunctional effector cells.
CRC-Th17 mediate protumorigenic effects in an
IL-17-dependent manner
The lack of association between IL-17-producing cells and
unfavourable clinical outcome was an unexpected ﬁnding con-
sidering the suggested protumorigenic activity of IL-17.7 8
This prompted us to investigate the functional properties of
CRC-Th17.
We conditioned CRC, endothelial cells (EC) and TASC with
supernatants obtained from CRC-Th17 clones or bulk popula-
tions. No signiﬁcant effects on cell proliferation were detected
(see online supplementary ﬁgure S5). VEGF production by CRC
cells was slightly increased by Th17 supernatants and it was
inhibited upon IL-17 neutralisation (ﬁgure 3A and see online
supplementary ﬁgure S6A). IL-6 release by EC and TASC was
strongly induced by Th17 supernatants in an IL-17-dependent
manner (ﬁgure 3B and see online supplementary ﬁgure S6B).
Thus, IL-17 released by CRC-Th17 cells appears to mediate
protumorigenic effects mainly by acting on EC and TASC.
CRC-Th17 promote neutrophil recruitment and activation
We next investigated the molecular background underlying the
association between Th17 and CD16+MPO+ myeloid cells or
CD8+CTLs. The phenotypic analysis ruled out the possibility
that neutrophils or CTLs could be the IL-17 producers.
Alternatively, we investigated whether Th17 cells may recruit
these cell populations into tumour tissues either directly or by
eliciting chemokine release by stromal cells.33 34
Neutrophils are known to migrate in response to IL-8.
Indeed, supernatants from CRC-Th17 clones and bulk popula-
tions induced vigorous neutrophil migration in an
IL-8-dependent manner (ﬁgure 4A and see online supplemen-
tary ﬁgure S7A, respectively), whereas other Th17 cytokines,
including IL-17 and GM-CSF, appeared to play no role in this
phenomenon (ﬁgure 4A and see online supplementary ﬁgure
S7B). Interestingly, exposure of neutrophils to Th17 superna-
tants also signiﬁcantly enhanced MPO release, independently of
IL-17, IL-8 or GM-CSF (ﬁgure 4B and see online supplemen-
tary ﬁgure S7C). Thus, CRC-Th17 might directly promote neu-
trophil recruitment and activation into CRC.
CRC-Th17 favour CTL recruitment by triggering chemokine
release from EC
In line with previous ﬁndings,35 circulating and tumour-
inﬁltrating CTLs were found to express CCR5 and CXCR3
receptors (ﬁgure 5A), enabling them to respond to CCL5 and
CXCL9/CXCL10, respectively.
These chemokines were all expressed on whole CRC tissues
(ﬁgure 5B). Upon sorting of tumour, stromal and EC from spe-
cimens, CCL5 and CXCL10 were expressed at the highest level
within the endothelial compartment (ﬁgure 5C), whereas no
Table 1 Association of IL-17 lymphocyte count and
clinicopathological features in CRC (n=1148)
Clinicopathological features
IL-17* lymphocyte count
p ValueMedian/mean Min–max
All 3/13.8 0–350
Tumour location
Right-sided 3/12.6 0–200 0.94†
Left-sided 3/14.3 0–332 0.13‡
Rectum 4/13.7 0–350
MMR status
Proficient 3/13.6 0–350 0.18
Deficient 4/14.5 0–167
pT stage
pT1–2 5.5/15.1 0–150 0.03
pT3–4 3/13.7 0–350
pN stage
pN0 4/15.5 0–350 0.03
pN1–2 3/12.3 0–350
Tumour grade
G1–2 4/14.2 0–350 0.01
G3 2/12.1 0–200
Vascular invasion
Absent 4/15.1 0–350 0.03
Present 3/10.7 0–250
Tumour border
Pushing 4/12.3 0–250 0.78
Infiltrating 3/14.9 0–350
Peritumoral lymphocytic inflammation
Absent 3/13.4 0–350 <0.001
Present 7.5/15.8 0–250
Local recurrence
Absent 1/8.5 0–350 0.35
Present 1/6.1 0–200
Distant metastasis
Absent 1/8.2 0–350 0.10
Present 1/3.8 0–30
Death
Censured 3/14.1 0–350 0.5
Present 4/13.8 0–332
p Value calculated according to the Mann–Whitney test. Significant p values are
shown in bold.
*As assessed by staining I (see ‘Materials and methods’).
†Right-sided versus left-sided.
‡Right-sided or left-sided versus rectum.
CRC, colorectal cancers; IL, interleukin; MMR, mismatch repair.
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CXCL9 was detected. EC exposure to CRC-Th17 supernatants
strikingly enhanced their ability to release CCL5 and CXCL10
(ﬁgure 5D) and to promote CTL migration (ﬁgure 5E). Notably,
these effects were not elicited by IL-17, nor were they inhibited
after IL-17 neutralisation, but instead appeared to depend on
Th17-derived TNF-α (ﬁgure 5F, G and see online supplementary
ﬁgure S8). Thus, Th17 may favour CTL recruitment into CRC
by triggering chemokine release from tumour-associated EC.
CRC-Th17 directly attract CTLs in vitro
Intriguingly, we observed that supernatants from CRC-Th17
bulks and clones signiﬁcantly induced CTL migration also in the
absence of EC (ﬁgures 5E, 6A and see online supplementary
ﬁgure S9A), thus suggesting that Th17 may release chemoattrac-
tants directly acting on CTLs.
In CRC-Th17 supernatants we detected signiﬁcant amounts
of CCL5, in addition to CCL20, a known Th17-derived
Figure 2 Colorectal cancers (CRC)-inﬁltrating interleukin (IL)-17+ cells are polyfunctional Th17. Single cell suspensions from freshly excised clinical
specimens of CRC and corresponding tumour-free colonic mucosa (Ctr) and peripheral blood mononuclear cells from healthy donors (PBMC HD) or
patients with CRC (PBMC Pz), were incubated with phorbol 12-myristate 13-acetate (PMA)/ionomycin/brefeldin for 5 h. Surface staining for speciﬁc
cell population markers and intracellular staining for Foxp3 and cytokines was then performed. (A) Representative ﬂow cytometric analysis of CRC
inﬁltrates stained for IL-17 and the indicated cell-speciﬁc markers. Tumour-inﬁltrating cells are gated based on physical parameters, as deﬁned by
analysis of autologous PBMC. (B) Frequencies of cells positive for the indicated markers within gated IL-17+ cells. Means are indicated by bars.
Numbers of samples evaluated for each marker are indicated in parentheses. (C) Frequencies of IL-17+ cells on gated CD3+ T cells obtained from
PBMC HD or PBMC CRC and single cell suspensions from freshly excised clinical specimens of Ctr and corresponding CRC. Means are indicated by
bars. Numbers of samples evaluated for each marker are indicated in parentheses. Statistical signiﬁcance was assessed by t test. (D) Representative
ﬂow cytometric analysis of intracellular cytokine staining on gated CRC-inﬁltrating CD3+CD4+ cells. (E) Frequencies of cells positive for the indicated
cytokines gated on CD3+CD4+ IL-17+ T cells. Means are indicated by bars. Numbers of samples evaluated for each cytokine are indicated in
parentheses. GM-CSF, granulocyte-macrophage colony stimulating factor; IFN, interferon; TNF, tumour necrosis factor.
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chemokine (ﬁgure 6B and see online supplementary ﬁgure S9B).
CTL migration was marginally impaired by CCL5 depletion,
whereas it was markedly reduced upon CCL20 removal (ﬁgure
6C). However, CCL5 increased CTL migration to low CCL20
concentrations (ﬁgure 6D), thus revealing a synergism between
these two chemokines. CCR6, the receptor for CCL20, was
expressed on a subset of CRC-inﬁltrating CTLs (ﬁgure 6E).
Frequencies of CCR6+CTLs were signiﬁcantly higher in CRC
than in autologous control tissues or PBMC (ﬁgure 6E).
Importantly, most CCR6+CTLs (up to 62±10%) also expressed
CCR5 (ﬁgure 6F). Furthermore, CCR5+CCR6+CTLs were
positive for TIA-1 (ﬁgure 6F), a cytotoxic granule-associated,
RNA-binding protein whose expression by CRC-inﬁltrating
CTLs is associated with survival advantage.28 Thus, through
CCL5 and CCL20 CRC-Th17 target highly cytotoxic T cells.
CRC-Th17 cells promote CTL recruitment into CRC tissues
We next assessed whether Th17-mediated effects might be rele-
vant for CTL recruitment into tumours.
We engineered tridimensional tumour-like tissues by culturing
HT29 cells on collagen scaffolds in perfused bioreactors31 36
(see online supplementary ﬁgure S10A, B). CRC-Th17 were
added into the system under perfusion, allowing their localisa-
tion in proximity of tumour nests (see online supplementary
ﬁgure S10C) and were subsequently activated (ﬁgure 7A).
Perfusion was then stopped and CTLs were applied. After an
overnight incubation, tumour inﬁltration by CTLs was evaluated
(ﬁgure 7B, C and see online supplementary ﬁgure S10D). CTLs
were found in tumour-like tissues, in proximity of tumour cells
(ﬁgure 7B) and their frequencies were signiﬁcantly higher in the
presence of activated CRC-Th17 (ﬁgure 7C).
Accordingly, when CTLs were adoptively transferred in
tumour-bearing mice together with Th17, signiﬁcantly higher
numbers of tumour-inﬁltrating CTLs were detected as compared
with mice transferred with CTLs alone (ﬁgure 7D). Thus,
CRC-Th17 directly attract CTLs into tumours.
These ﬁndings suggested that CRC-Th17 localised into the
tumour nests might play a beneﬁcial role by recruiting CTLs
close to tumour cells. Indeed, when we evaluated the prognostic
signiﬁcance of IL-17+ cells according to their localisation, the
presence of intraepithelial, but not of stromal IL-17+ cells, posi-
tively correlated with absence of local recurrence and prolonged
relapse-free survival (see online supplementary table S2 and
ﬁgure 8).
Figure 3 Colorectal cancers (CRC)-Th17 mediate protumorigenic effects in an interleukin (IL)-17-dependent manner. Endothelial cells (EC),
tumour-associated stromal cells (TASC) and CRC cell lines (LS180, COLO205) were conditioned for 24 h with CRC-Th17 supernatants untreated (Th17
SN) or pretreated with anti-IL-17 neutralising antibodies (Th17+ anti-IL-17). Vascular endothelial growth factor (VEGF) (A) or IL-6 (B) release was
measured in culture supernatants by ELISA. Statistical signiﬁcance was analysed by one-way analysis of variance. Data refer to experimental
triplicates from two independent experiments performed with supernatants from two different clones. Ctr, healthy colonic tissue.
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DISCUSSION
The goal of our study was to investigate the clinical relevance
of CRC-inﬁltrating, IL-17-producing cells in a large patient
cohort and to characterise in detail their phenotypes and
functional properties. Upon analysis of >1000 primary CRC
cases, we found that CRC-inﬁltrating IL-17+ cells are not
themselves predictive of patient survival but, their prognostic
signiﬁcance rather appears to depend on their localisation
within CRC tissue. Indeed, intraepithelial, but not stromal
IL-17+ cells, were associated with improved prognosis. Ex
vivo analysis showed that tumour-inﬁltrating, IL-17-produ-
cing cells mostly consist of polyfunctional Th17, releasing a
spectrum of cytokines and chemokines, in addition to IL-17.
Through IL-17, CRC-Th17 triggered the release of protu-
morigenic factors mainly by tumour-associated stroma.
However, by releasing additional chemokines, they also
appeared to contribute to the recruitment of beneﬁcial
effector cells into tumours. In particular, through IL-8 they
promoted the recruitment of CD16+ MPO+ neutrophils.
Most importantly, through CCL5 and CCL20, they attracted
cytotoxic CTLs into tumour nests. Accordingly, in our patient
cohort, CRC inﬁltration by Th17 cells correlated with that by
neutrophils and CTLs.
Based on these ﬁndings, the lack of association between total
numbers of Th17 cells and prognostic signiﬁcance is not surpris-
ing. Indeed, the potentially negative impact of IL-17 is probably
counterbalanced by recruitment of beneﬁcial effector cells. In
previous reports, however, an association between total IL-17+
inﬁltrates and unfavourable clinical outcome was observed.7 8
Although a few differences in the protocol used in our study as
compared with others must be acknowledged (ie, in our work
IL-17 positivity was assessed by three independent observers,
whereas in the study by Tosolini et al8 the TMA staining was
quantiﬁed by image software), the discrepancy between ours
and previous studies probably relies on the different numbers of
cases evaluated (527 and <2008 vs 1148). Notably, we obtained
comparable results upon TMA staining with two different
IL-17-speciﬁc antibodies.7 8
Importantly, our study reveals a previously unrecognised posi-
tive prognostic signiﬁcance of intraepithelial Th17 cells, suggest-
ing a critical contribution of these cell subsets to the
recruitment of CTLs and neutrophils into tumour nests.
IL-17-production by CD4+ cells has been previously
reported in CRC.37–39 However, whether other cell types may
also contribute to IL-17 release within CRC tissues remained to
be assessed. We observed that most IL-17+ cells are CD3+
CD4+ T cells, expressing CD45RO and CCR6 and including a
subset of Foxp3+ cells. In contrast, no signiﬁcant IL-17 produc-
tion was seen within other cell subsets, including CTLs and
innate lymphoid and myeloid cell populations.
IL-17-producing Foxp3+ cells were previously described
within CRC tissues,37 38 40 but their functional role remains
unclear. Remarkably, CRC inﬁltration by Tregs correlates with
prolonged patient survival.2 3
A recent study reported γδT cells as a major IL-17 source in
human CRC.41 We also observed considerable percentages of
γδT cells within CRC inﬁltrates, but only a negligible fraction of
them showed IL-17 production ability. However, the patients
examined in the study by Wu et al41 and in our study belong to
two different ethnic and geographical groups (ie, China and
Switzerland, respectively), therefore probably differing in the
composition of their gut ﬂora.42 This may be of relevance when
considering cell populations, such as γδT and Th17 cells, whose
function is modulated by deﬁned microbiota.22 43 44 Thus, this
discrepancy may be due to the presence, in the patients evalu-
ated, of distinct gut microbial species, possibly driving preferen-
tial expansion of IL-17-producing γδTor Th17 cells.
The ability of Th17 to recruit effector cells appears to be
dependent on their capacity to release cytokines other than
IL-17. Indeed, Th17 supernatants promoted neutrophil recruit-
ment in an IL-8-dependent fashion and enhanced secretion of
MPO, a lysosomal enzyme possibly involved in the mechanisms
underlying the favourable effect of MPO+ neutrophils in
CRC.4 In addition, CRC-Th17 supernatants activated tumour-
associated EC to release CCL5 and CXCL10, attracting CTLs.
Importantly, tumour-inﬁltrating Th17 proved capable of directly
Figure 4 Colorectal cancers (CRC)-inﬁltrating Th17 favour recruitment and activation of neutrophils. (A) Migration of neutrophils, puriﬁed from
blood of healthy donors, towards control medium (Ctr), supernatants of Th17 clones expanded from CRC-inﬁltrating cells (Th17 SN) or Th17
supernatants pre-treated with anti-interleukin (IL)-17 (Th17 SN+ anti-IL-17), anti-IL-8 (Th17 SN+ anti-IL-8), or anti-granulocyte-macrophage colony
stimulating factor (anti-GM-CSF antibodies) (Th17 SN+ anti-GM-CSF), was evaluated after 90 min incubation by ﬂow cytometry. Data refer to
experimental triplicates from three independent experiments performed with supernatants from three different clones. Means±SD are depicted.
Statistical signiﬁcance was assessed by one-way analysis of variance (ANOVA). (B) Myeloperoxidase (MPO) release by neutrophils exposed to control
medium (Ctr), Th17 supernatants (Th17 SN) or Th17 supernatants pretreated with anti-IL-17, IL-8 or GM-CSF antibodies was assessed after 4 h
incubation by ELISA. Means±SD are depicted. Data refer to experimental triplicates from three independent experiments performed with
supernatants from three different clones. Statistical signiﬁcance was assessed by one-way ANOVA.
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Figure 5 Th17 cells favour recruitment of CD8+ T cells by triggering chemokine release from endothelial cells (EC). (A) Peripheral blood cells (PB,
n=7) and tumour cell suspensions from patients with colorectal cancer (CRC) (n=12) were surface stained for CD8 in combination with the indicated
chemokine receptors. Left panels: representative ﬂow cytometric analysis. Right panels: percentages of CD8+ cells expressing the indicated
chemokine receptors. Means±SD are depicted. (B) The expression of the indicated chemokine genes was assessed on CRC samples (n=21) by
quantitative PCR. Expression levels relative to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) are depicted. (C) Endothelial, tumour and stromal
cells were sorted from cell suspensions derived from CRC specimens by ﬂow cytometry, based on CD31, EpCAM and CD90 expression, respectively.
mRNA levels of the indicated chemokine genes were assessed in sorted cells by quantitative PCR. Gene expression levels relative to GAPDH are
depicted. Data refer to analysis of one representative sample out of four. (D) Chemokine release by HMEC cells untreated (EC) or exposed overnight
to recombinant interleukin-17 (rIL-17; 50 ng/mL) (EC+IL-17) or to Th17 clone supernatants (EC+Th17 SN), was measured by ELISA. Chemokine
content in Th17 SN was also assessed as control. Data refer to experimental triplicates from three experiments performed with three different clones
from one patient. Means±SD are depicted. Statistical signiﬁcance was assessed by one-way analysis of variance (ANOVA). (E) Migration of CD8+ T
cells, puriﬁed from peripheral blood mononuclear cells (PBMC) of healthy donors, towards supernatants of HMEC cells untreated (EC), or exposed to
rIL-17 (50 ng/mL) (EC+IL17) or Th17 supernatants (EC+Th17), was assessed after 90 min of incubation by ﬂow cytometry. Migration towards Th17
supernatants (Th17 SN) was also assessed as control. Data refer to experimental triplicates from three experiments performed with three different
clones from one patient. Means±SD are depicted. Statistical signiﬁcance was assessed by one-way ANOVA. (F and G) Chemokine contents (F) and
cytotoxic T lymphocyte (CTL) chemoattraction capacity (G) of supernatants from HMEC cells untreated (EC), exposed overnight to Th17 supernatants
(EC+Th17 SN), or exposed to Th17 supernatants pretreated with anti-IL-17 (EC+Th17+anti-IL-17) or anti-tumour necrosis factor α (anti-TNF-α)
antibodies (EC+Th17+anti-TNF-α). Data refer to three experiments performed with supernatants of Th17 bulk populations derived from three
different samples. Means±SD are depicted. Statistical signiﬁcance was assessed by one-way ANOVA.
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recruiting highly cytotoxic TIA-1+ CCR5+ CCR6+ CTLs
through own production of CCL5 and CCL20. Interestingly,
CCL5 and CCL20 appeared to synergise. Although CCL5 could
not itself induce CTL migration, it could increase CTL response
to low CCL20 concentrations.
In a melanoma mouse model, Th17 have been previously
shown to favour tumour inﬁltration by CTLs, ultimately mediat-
ing tumour eradication.45 46 These in vivo models, however,
could not discriminate between direct and indirect effects of
Th17 on CTL recruitment. Therefore, to assess the relevance of
the direct Th17-mediated effects on CTLs, we took advantage
of an engineered tridimensional tumour tissue inﬁltrated by
Th17 cells, in the absence of EC. Furthermore, we adoptively
transferred human CTLs and Th17 in immunodeﬁcient mice
bearing human tumour xenografts. Strikingly, in both experi-
mental systems, the presence of activated Th17 cells markedly
enhanced CTL recruitment into the tumour.
These data suggest that Th17 cells may promote tumour inﬁl-
tration by CTLs through a double axis: on the one hand, they
might favour EC activation leading to CTL recruitment from the
Figure 6 Th17 cells directly attract
cytotoxic CD8+ T cells. (A) Migration
of CD8+ T cells towards control
medium (Ctr) or supernatants of two
different colorectal cancer (CRC)-Th17
clones (Th17.15 SN and Th17.71 SN),
was assessed after 90 min incubation
by ﬂow cytometry. (B) Chemokine
release by Th17 clones (Th17.15 and
Th17.71), activated with plate bound
anti-CD3 and soluble anti-CD28
antibodies for an overnight period, was
measured by ELISA. Means±SD of
experimental triplicates are depicted.
(C) Migration of CD8+ T cells towards
Th17 clone supernatants depleted of
CCL5 (Th17 SN−CCL5), CCL20 (Th17
SN−CCL20) or both (Th17 SN−CCL5
−CCL20), relative to control (migration
towards untreated Th17 supernatants).
(D) Migration of CD8+ T cells towards
Th17 clone supernatants (Th17 SN) or
towards low or high doses of
recombinant CCL20 (300 and 1000 ng/
mL, respectively) and CCL5 (60 and
200 ng/mL, respectively). (A–D) Means
±SD from experimental triplicates are
depicted. One representative
experiment out of two is shown.
Statistical signiﬁcance was assessed by
one-way analysis of variance (ANOVA).
(E) Representative ﬂow cytometric
analysis of CRC inﬁltrates stained for
CD8 and CCR6 markers (left panel).
Frequencies of CCR6+CD8+ T cells
were measured by ﬂow cytometry in
peripheral blood mononuclear cells of
healthy donors (PBMC HD n=7) or
patients with CRC (PBMC Pz n=12)
and in single cell suspensions from
freshly excised clinical specimens of
tumour-free colonic mucosa (Ctr) and
corresponding CRC (n=12). Means are
indicated by bars. Statistical
signiﬁcance was assessed by t test. (F)
Left and middle panels: representative
ﬂow cytometric analysis of
CRC-inﬁltrating CD8+ T cells stained
for CCR6, CCR5 and TIA-1. Right
panel: frequencies of CCR6+ CCR5+
cells within TIA-1- or TIA-1+
CRC-inﬁltrating CD8+ T cells (n=7).
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Figure 7 Th17 cells promote recruitment of cytotoxic CD8+ T cells into colorectal cancer (CRC) tissues. (A) CRC-Th17-inﬁltrating engineered tumour
tissues (see online supplementary ﬁgure S10) were left untreated or were activated by adding CytoStim to the perfusion medium. Culture media were
collected 20 h later and chemokine contents were assessed by ELISA. Statistical signiﬁcance was assessed by Mann–Whitney test. (B and C) Three hours
after Th17 activation, the perfusion in the bioreactor was stopped and CD8+ T cells were added to the system. After an overnight period, scaffolds were
removed and tumour inﬁltration by CD8+ T cells was evaluated by immunoﬂuorescence analysis upon staining with CD4- and CD8-speciﬁc antibodies (B)
and by ﬂow cytometry upon staining of single cell suspensions with EpCAM-, CD4- and CD8-speciﬁc antibodies (C). Percentages of CD8+ cells in tumour
tissues inﬁltrated by resting or activated Th17 cells are reported. Means±SD from three experimental replicates performed with one Th17 clone are
depicted. Statistical signiﬁcance was assessed by Mann–Whitney test. (D) CSFE+CD8+ T cells were adoptively transferred in tumour bearing mice alone
or together with equal numbers of CRC-Th17 (four mice/condition). Absolute numbers of CD8+CSFE+ T cells were evaluated by ﬂow cytometry upon
staining of tumour and Th17 cells with anti-EpCAM and anti-CD4 antibodies, respectively. Statistical signiﬁcance was assessed by Mann–Whitney test.
Figure 8 Intra-epithelial localisation of interleukin (IL)-17+ cells correlates with prolonged relapse-free survival (RFS) survival. Kaplan–Meier curves
illustrating RFS probability according to inﬁltration by IL-17+ cells within the epithelial (left panel) or stromal (right panel) compartment. Numbers
of deaths/total cases within each category are indicated. Statistical signiﬁcance was assessed by log-rank test.
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blood stream, on the other, they might directly guide the posi-
tioning of CTLs in proximity of tumour cells. Altogether our
data reveal a positive contribution of Th17 cells to beneﬁcial anti-
tumour immune responses developing in CRC and underline
their pleiotropic function resulting from the production of a
broad spectrum of cytokines and chemokines beyond IL-17.
This may, at least partially, explain the discrepancies between
results obtained from studies evaluating the effects of IL-17 or
IL-17 signalling only and those examining functions of the
whole Th17 cell subset.47–50
Our ﬁndings have important clinical implications. Indeed, the
positive contribution of Th17 to anti-tumour immune responses
should not be disregarded when developing new IL-17/Th17
targeted treatments in CRC, possibly resulting in impaired
tumour inﬁltration by beneﬁcial effector cells.
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